Compare DOGZ & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOGZ | MRKR |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5M | 18.7M |
| IPO Year | 2017 | 2010 |
| Metric | DOGZ | MRKR |
|---|---|---|
| Price | $0.98 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 711.3K | 77.3K |
| Earning Date | 04-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $0.83 |
| 52 Week High | $15.61 | $2.46 |
| Indicator | DOGZ | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 48.64 |
| Support Level | $0.94 | $1.10 |
| Resistance Level | $1.06 | $1.36 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.43 | 30.43 |
Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).